Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ibrutinib as Prophylaxis for Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

NCT06271616 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06271616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06271616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ibrutinib as Prophylaxis for Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
December 13, 2024
Completion date
May 14, 2026
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease, hematopoietic and lymphatic system neoplasm